Prime Medicine annual stock-based compensation
2020
2021
2022
2023
2024
2025
Prime Medicine Stock-Based Compensation Growth & History (PRME)
Prime Medicine's stock-based compensation was $29.3M for fiscal 2025.
View full Prime Medicine company overviewPrime Medicine annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $29.3M | $3.2M | +12.28% |
| 2024 | 2024-12-31 | $26.1M | $12.2M | +87.40% |
| 2023 | 2023-12-31 | $13.9M | $7.5M | +115.36% |
| 2022 | 2022-12-31 | $6.5M | $4.7M | +269.93% |
| 2021 | 2021-12-31 | $1.7M | $1.4M | +346.55% |
| 2020 | 2020-12-31 | $391,000 | — | — |
Prime Medicine quarterly stock-based compensation
Q3.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $4.9M | −$1.5M | −23.08% |
| Q1 2026 | 2026-03-31 | $4.6M | −$1.0M | −18.25% |
| Q4 2025 | 2025-12-31 | $4.5M | −$1.4M | −24.00% |
| Q3 2025 | 2025-09-30 | $12.7M | $5.9M | +86.71% |
| Q2 2025 | 2025-06-30 | $6.3M | −$1.8M | −21.83% |
| Q1 2025 | 2025-03-31 | $5.7M | $472,000 | +9.06% |
| Q4 2024 | 2024-12-31 | $5.9M | $1.5M | +34.14% |
| Q3 2024 | 2024-09-30 | $6.8M | $2.6M | +61.89% |
| Q2 2024 | 2024-06-30 | $8.1M | $4.5M | +125.82% |
| Q1 2024 | 2024-03-31 | $5.2M | $3.5M | +209.88% |
| Q4 2023 | 2023-12-31 | $4.4M | $1.9M | +72.07% |
| Q3 2023 | 2023-09-30 | $4.2M | $2.8M | +197.60% |
| Q2 2023 | 2023-06-30 | $3.6M | $2.2M | +166.39% |
| Q1 2023 | 2023-03-31 | $1.7M | $558,000 | +49.69% |
| Q4 2022 | 2022-12-31 | $2.6M | — | — |
| Q3 2022 | 2022-09-30 | $1.4M | $1.1M | +317.99% |
| Q2 2022 | 2022-06-30 | $1.3M | — | — |
| Q1 2022 | 2022-03-31 | $1.1M | — | — |
| Q3 2021 | 2021-09-30 | $339,000 | — | — |
Prime Medicine stock-based compensation trends
Over the last five fiscal years, Prime Medicine's stock-based compensation increased from $391,000 to $29.3M, a change of $28.9M. The latest reported quarter, Q2 2026, shows $4.9M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Prime Medicine source filings ↗